Iodine 131

Description

Overview:

Iodine-131 (I‑131) is a widely used radioactive isotope in the field of nuclear medicine. Emitting both beta and gamma radiation, I‑131 is essential in the diagnosis and treatment of thyroid diseases, including hyperthyroidism and differentiated thyroid cancer. It is typically administered in liquid or capsule form and is produced in nuclear reactors via neutron irradiation of tellurium.

Key Features:

• Emits both β (beta) and γ (gamma) radiation

• Suitable for targeted radiotherapy and imaging

• Available in solution or capsule form

• Short half-life (~8 days) ensures rapid decay post-treatment

• Delivered in lead-shielded vials for radiation safety

• Supplied under strict regulatory and medical licensing guidelines

Applications:

• Therapeutic Use:

  • Ablation of residual thyroid tissue after thyroidectomy

  • Treatment of thyroid cancer and hyperthyroidism

• Diagnostic Use:

  • Thyroid uptake scans

  • Whole-body scans post-treatment

• Research Use:

  • Radiotracer studies in metabolic pathways and biodistribution

Optional Specifications (Example – customizable):

• Form: Sodium iodide (NaI) in sterile solution or gel capsule

• Activity Levels: Typically 1–10 mCi (therapy), up to 100 mCi (cancer treatment)

• Half-life: 8.02 days

• Radiation Emission:

  • Beta: 606 keV (main energy)

  • Gamma: 364 keV

• Packaging: Shielded Type-A transport vials or ampoules

• Storage: In shielded lead container at ≤25°C

⚠️ Regulatory Notice:

I-131 is a controlled radioactive substance. Its production, distribution, handling, and administration must comply with national regulatory authority guidelines (e.g., BAERA in Bangladesh or equivalent). Only licensed facilities and authorized medical professionals may receive and administer this isotope.